赛妥珠单抗治疗96周对中轴型脊柱关节炎脊柱及骶髂关节MRI炎症的影响及临床与MRI结局的关联
RAPID-axSpA试验显示,赛妥珠单抗(CZP)治疗中轴型脊柱关节炎(axSpA)患者12周时脊柱和骶髂关节MRI炎症评分较安慰剂显著改善,并维持至96周;影像学与无影像学axSpA趋势相似。达到临床缓解与MRI炎症消失的一致性有限。
要点
- CZP组12周SPARCC和Berlin评分改善显著优于安慰剂,并维持至96周。
- 12周时骶髂关节、脊柱及两者兼有的MRI缓解率分别为52.6%、62.0%和37.9%。
- 临床缓解与MRI炎症消失的一致性有限。
核心结论
- 赛妥珠单抗可减轻放射学及非放射学中轴型脊柱关节炎患者脊柱和骶髂关节MRI炎症,改善维持至96周。
- 相当比例患者达到MRI缓解,但临床缓解与当前MRI炎症消失定义的一致性有限。
研究设计与样本
- RAPID-axSpA(NCT01087762)为双盲、安慰剂对照至24周、剂量盲至48周、开放标签至204周的试验。
- 患者随机接受赛妥珠单抗或安慰剂,进入剂量盲期的安慰剂患者重新随机接受赛妥珠单抗。
- 基线、12周、48周和96周MRI由2名独立评审者评分:骶髂关节用SPARCC,脊柱用Berlin修改的AS spine MRI评分系统。
- MRI数据集共163例患者(赛妥珠单抗109例;安慰剂54例)。
主要发现
- 12周时MRI评分较基线平均变化:SPARCC为-4.8(SD 8.6)vs -1.6(7.8),p<0.001;Berlin为-2.9(4.2)vs 0.2(4.8),p<0.001。
- 改善维持至96周。
- 12周时基线有骶髂关节MRI炎症者52.6%达到MRI缓解,脊柱为62.0%,两者兼有者为37.9%。
- MRI缓解率维持至96周,放射学与非放射学axSpA趋势相似。
- 96周时,达到与未达到临床缓解的患者中分别有57.5%与65.9%达到MRI缓解。
关键数值与推荐
- 炎症阈值:SPARCC≥2;Berlin>2。
- 缓解阈值:骶髂关节SPARCC<2;脊柱Berlin≤2;临床ASDAS inactive disease(<1.3)。
临床怎么用
- 赛妥珠单抗可用于改善axSpA患者脊柱和骶髂关节MRI炎症,疗效维持至96周。
- 临床缓解与MRI炎症消失不一致,评估病情时需结合临床与影像学。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report MRI outcomes and explore the relationship between clinical remission and MRI inflammation in patients with axial spondyloarthritis (axSpA) from the RAPID-axSpA trial, including radiographic (r-)axSpA and non-radiographic (nr-)axSpA. METHODS: RAPID-axSpA (NCT01087762) was double-blind and placebo-controlled to week 24, dose-blind to week 48 and open-label to week 204. Patients were randomised to certolizumab pegol (CZP) or placebo. Placebo patients entering dose-blind were rerandomised to CZP. MRIs performed at baseline, weeks 12, 48 and 96 were scored by 2 reviewers independently: Spondyloarthritis Research Consortium of Canada (SPARCC) for sacroiliac (SI) joints; Berlin modification of the Ankylosing Spondylitis spine MRI scoring system for disease activity (Berlin) for spine. Inflammation thresholds: SPARCC≥2; Berlin>2. Remission thresholds: SPARCC<2 (SI joints); Berlin≤2 (spine); Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (<1.3, clinical). RESULTS: Across 163 patients in the MRI set (109 CZP; 54 placebo), week 12 mean changes from baseline in MRI scores were greater for CZP versus placebo: SPARCC: -4.8 (SD 8.6) vs -1.6 (7.8; p<0.001); Berlin: -2.9 (4.2) vs 0.2 (4.8; p<0.001). Improvements were maintained to week 96. Week 12 MRI remission was achieved by 52.6% of patients with baseline MRI inflammation in SI joints, 62.0% in the spine and 37.9% of patients with both. MRI remission rates were sustained to week 96, with similar trends in r-axSpA and nr-axSpA. At week 96, 57.5% vs 65.9% of patients achieving versus not achieving clinical remission had MRI remission. CONCLUSIONS: CZP reduced inflammation in the spine and SI joints in patients with r-axSpA and nr-axSpA, with improvements maintained over 96 weeks. Substantial proportions of patients achieved MRI remission. Concordance between clinical remission and current definitions of absence of MRI inflammation was limited. TRIAL REGISTRATION NUMBER: NCT01087762; Post-results.
引用
- Braun J, Baraliakos X, Hermann KG, et al. Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. RMD Open. 2017. PMID: 28848654. doi:10.1136/rmdopen-2017-000430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。